-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On May 21, 2021, Shanghai Mengke Pharmaceutical Co.
, Ltd.
and Biocytometer (Beijing) Pharmaceutical Technology Co.
, Ltd.
reached a strategic cooperation intention.
The two parties will work together to develop fully human antibody drugs in the field of infectious diseases
.
This cooperation will be based on the fully human antibody mice (RenMab®, RenLite®, RenNano®) based on Biocytogen’s independent intellectual property rights, and the development of high-efficiency antibodies and a complete preclinical pharmacology and drug efficacy research platform.
The experience in the field of anti-infection realizes technological complementarity and collaborative innovation, and jointly promotes drug development in related fields
.
Mengke Pharmaceutical is a leading company in the development of new anti-drug-resistant bacteria.
The core team members have rich experience in the development of new anti-infective drugs, leading or participating in the development and sales of many new anti-infective drugs on the market around the world
.
Since its establishment in 2007, the company has established multiple R&D pipelines including contizolamide (code-named MRX-I), MRX-4, MRX-8 and other clinical-stage innovative drugs
Biocytometer has established an efficient antibody drug discovery and in vivo screening platform based on gene-edited model animals, combined with strong clinical development capabilities to form a highly integrated bio-innovative drug development system.
With its solid technological innovation strength, The anti-" plan continues to promote the output of new drugs, and has established extensive cooperation with more than 200 pharmaceutical companies including 70% of the global Top 20.
In 2020, it has reached over 10 new drug joint development projects with many new drug research and development companies
.
Dr.
Yuan Zhengyu, CEO of Mengke Pharmaceuticals, said about this strategic cooperation: This cooperation is an important step for Mengke Pharmaceuticals to extend its R&D capabilities to areas other than traditional antibacterial drugs
.
Biocytogen's fully human antibody mouse platform has solid and complete verification data.
Biocytogen CEO Dr.
Shen Yuelei said: It is a great honor to cooperate with Mengke Pharmaceutical.
Infectious diseases have always affected human health, especially the outbreak of the new coronavirus, which has made everyone pay more and more attention to the treatment of infectious diseases
.
Mengke Pharmaceuticals has established a core competitive position in the field of anti-multidrug-resistant "super bacteria" infections, and its first new antibacterial drug will be launched soon
